Huennekens FM (1994). „The methotrexate story: a paradigm for development of cancer chemotherapeutic agents”. Adv. Enzyme Regul.34: 397–419. DOI:10.1016/0065-2571(94)90025-6. PMID7942284.
McGuire JJ (2003). „Anticancer antifolates: current status and future directions”. Curr. Pharm. Des.9 (31): 2593–613. DOI:10.2174/1381612033453712. PMID14529544.
Hawser S, Lociuro S, Islam K (March 2006). „Dihydrofolate reductase inhibitors as antibacterial agents”. Biochem. Pharmacol.71 (7): 941–8. DOI:10.1016/j.bcp.2005.10.052. PMID16359642.
Huennekens FM (1994). „The methotrexate story: a paradigm for development of cancer chemotherapeutic agents”. Adv. Enzyme Regul.34: 397–419. DOI:10.1016/0065-2571(94)90025-6. PMID7942284.
McGuire JJ (2003). „Anticancer antifolates: current status and future directions”. Curr. Pharm. Des.9 (31): 2593–613. DOI:10.2174/1381612033453712. PMID14529544.
Hawser S, Lociuro S, Islam K (March 2006). „Dihydrofolate reductase inhibitors as antibacterial agents”. Biochem. Pharmacol.71 (7): 941–8. DOI:10.1016/j.bcp.2005.10.052. PMID16359642.